

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (currently amended) An A pharmaceutical composition comprising:
an endogenous protein-dalbavancin complex, said endogenous protein-dalbavancin complex
comprising both a 1:1 complex of protein to dalbavancin₁ and a 1:2 complex of protein to dalbavancin₁
or a mixture thereof,
wherein said composition is sterile, and
wherein said endogenous protein is human serum albumin.
2. (original) The complex of claim 1, wherein the dalbavancin comprises one or more of the A₀, A₁, B₀, B₁ and MAG dalbavancin components
3. (currently amended) A endogenous-dalbavancin protein complex formed in vivo by intravenous ~~administration~~ administration of a dalbavancin composition to a mammalian patient under conditions wherein the initial plasma concentration of dalbavancin is at least 200 mg/L and further wherein that least about 90% of the complex formed has a ratio of dalbavancin to protein of 1:1.
4. (original) The complex according to any of claims 1-3, which further comprises a stabilizer.
5. (canceled)
6. (canceled)
7. (original) The protein-dalbavancin complex of claim 1, wherein the complex is formed in vitro.
8. (original) The protein-dalbavancin complex of claim 1, wherein the complex is formed ex vivo.
9. (original) A protein-dalbavancin complex, wherein the ratio of protein molecules to dalbavancin molecules is 1:1.
10. (original) A protein-dalbavancin complex, wherein the ratio of protein molecules to dalbavancin molecules is 0.5:1.
11. (original) The protein-dalbavancin complex of claim 1 wherein the dalbavancin component of the complex retains at least about 10% of the antibacterial activity of free dalbavancin.
12. (original) The protein-dalbavancin complex of claim 1 wherein the complex permits systemic tissue distribution of dalbavancin in an individual when present in said individual.
13. (amended) [A] The pharmaceutical composition of claim 1 further comprising a pharmaceutically acceptable carrier and the protein-dalbavancin complex of claim 1.
14. (canceled)
15. (original) A pharmaceutical composition as in claim 13, wherein said composition is lyophilized.
16. (original) A pharmaceutical composition as in claim 13, wherein said composition is in a pharmaceutically acceptable form for administration to an individual.
17. (original) A pharmaceutical composition as in claim 16, wherein said composition is a pharmaceutically acceptable aqueous formulation.
18. (original) A pharmaceutical composition as in claim 16, wherein said individual is a mammal.

19. (original) A pharmaceutical composition as in claim 16, wherein said individual is a human.
20. (original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier, a protein-dalbavancin complex of claim 1, and a non-dalbavancin antibiotic or mixture of non-dalbavancin antibiotics.
21. (original) A pharmaceutical composition as in claim 20, wherein the non-dalbavancin antibiotic or mixture of antibiotics includes at least one antibiotic that is effective against a Gram negative bacterium.
- Claims 22-25. (canceled)
26. (original) A method for treating a bacterial infection in an individual in need thereof, said method comprising administering a therapeutically effective dose of the protein-dalbavancin complex of claim 1.
27. (original) The method of claim 26, wherein said therapeutically effective dose comprises an amount of protein-dalbavancin complex sufficient to provide a therapeutically effective serum level of dalbavancin in said individual for at least 5 days.
28. (original) A method as in claim 27, comprising administering first and second therapeutically effective doses of the protein-dalbavancin complex, wherein the amount of the second dose is about half or less than the amount of the first dose.
29. (currently amended) A method as in claim 22-or 26, wherein said administration is parenteral.
30. (original) A method as in claim 29, wherein said parenteral administration comprises controlled intravenous administration.
31. (original) A method as in claim 30, wherein said intravenous administration occurs over at least about 30 minutes.
32. (currently amended) A method as in claim 22-or 26, wherein the dose of dalbavancin is about 500 mg to about 1000 mg.
33. (currently amended) A method as in claim 22-or 26, wherein said bacterial infection comprises a Gram-positive bacterium.
34. (original) A method as in claim 33, wherein said Gram-positive bacterium is a penicillin-resistant bacterium.
35. (original) A method as in claim 33, wherein said Gram-positive bacterium is a multi-drug-resistant bacterium.
36. (currently amended) A method as in claim 22-or 26, wherein said bacterial infection comprises a skin and soft tissue infection (SSTI).
37. (original) A method as in claim 36, wherein said SSTI comprises *Staphylococcus aureus*.
38. (original) A method as in claim 36, wherein said SSTI comprises *Streptococcus pyogenes*.
39. (currently amended) A method as in claim 22-or 26, wherein said bacterial infection is reduced.
40. (currently amended) A method as in claim 22-or 26, wherein said bacterial infection is eliminated.
41. (currently amended) A method as in claim 22-or 26, wherein said individual is a mammal.
42. (original) A method as in claim 41, wherein said individual is a human.

43. (currently amended) A method as in claim 22-~~er~~ 26, further comprising administering an antibiotic effective against a Gram negative bacterium to the individual.

Claims 44-60 (canceled)

61. (original) A method for treating a bacterial infection in an individual in need thereof, said method comprising administering a pharmaceutically acceptable carrier, a therapeutically effective dose of a protein-dalbavancin complex of claim 1, and a non-dalbavancin antibiotic or mixture of non-dalbavancin antibiotics.

62. (original) The method of claim 61, wherein said therapeutically effective dose of a protein-dalbavancin complex comprises an amount of protein-dalbavancin complex sufficient to provide a therapeutically effective serum level in said individual for at least 5 days.

63. (original) A method as in claim 62, comprising administering first and second therapeutically effective doses of protein-dalbavancin complex, wherein the amount of the second dose is about half or less than the amount of the first dose.

64. (original) A method as in claim 61, wherein said non-dalbavancin antibiotic or mixture of non-dalbavancin antibiotics comprises at least one antibiotic that is effective against a Gram negative bacterium.

Claims 65-77 (canceled).

78. (currently amended) A kit comprising the ~~protein-dalbavancin complex~~ composition of claim 1 and instructions for use in a method of treatment for a bacterial infection.

79. (canceled)

80. (canceled)